Illumina, Inc. vs Johnson & Johnson — Stock Comparison
Illumina, Inc. (ILMN) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson narrowly edges Illumina, Inc. on Q·Score (7.1 vs 6.8 out of 10), led by Valuation (7.3 vs 4.8) and Quality (9.3 vs 8.5). Illumina, Inc. scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for JNJ (+10.7%) than for ILMN (-8.3%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 34% return on equity and 19% profit margins.
⚠ valuation metrics above sector average.
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ILMN vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Illumina, Inc. (ILMN) at 6.8/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ILMN or JNJ?
Illumina, Inc. (ILMN) scores higher on Growth (6.3/10 vs 5.1/10). Illumina, Inc. reports revenue growth (4.8% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ILMN or JNJ more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7.3/10 vs 4.8/10). ILMN trades at 27.3× P/E versus JNJ at 18.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ILMN vs JNJ?
There are 18 analysts covering ILMN with a consensus price target of $148.56, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ILMN or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 8.5/10). Net profit margin: ILMN at 19.4%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ILMN or JNJ?
Illumina, Inc. (ILMN) scores higher on Financial Health (7.6/10 vs 6.5/10). Market beta: ILMN at 1.49, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ILMN and JNJ?
Illumina, Inc. (ILMN) has a market capitalisation of $24.5B, while Johnson & Johnson (JNJ) has a market cap of $549.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →